Bax Degradation Assay for Tumor Survival and Progression
None
Inventor: Dou, Ping | Li, Benyi
Priority Number: US6692927B2
IPC Current: A61K003817 | G01N0033574 | G01N003368
US Class: 43500723 | 435004 | 43500721 | 43500792 | 436008 | 436063 | 436064 | 436086 | 436164 | 436174 | 530300 | 530350 | 530386 | 5303871 | 5303877
Assignee Applicant: University of South Florida,Tampa
Title: Bax degradation involvement in tumor survival and progression
Usefulness: Bax degradation involvement in tumor survival and progression
Summary: For diagnosis, prognosis, prevention and treatment of cancer using determinations of Bax degradation levels. For determining or predicting tumor aggressiveness, for screening for Bax degradation inhibitors, and for determining the efficacy of protease inhibitors to prevent Bax degradation. Levels of Bax degradation activity also predict response of tumor cells to proteasome inhibitors and other anticancer drugs, or determine the efficacy of prospective chemotherapeutic agents and/or radiation therapy for treating cancer.
Novelty: Determining Bax degradation activity in patient sample, useful in cancer diagnosis, prognosis, prevention/treatment, comprises e.g. incubating labeled Bax protein with protein extract from sample, and detecting signal from labeled protein
診斷/治療
癌症/腫瘤
美國
